Photo by julianhochgesang from unsplash
Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases. AVX001, a cPLA2α inhibitor, was investigated in a randomized, double‐blind, placebo‐controlled, split‐design, first‐in‐man study… Click to show full abstract
Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases. AVX001, a cPLA2α inhibitor, was investigated in a randomized, double‐blind, placebo‐controlled, split‐design, first‐in‐man study in patients with mild to moderate psoriasis.
Keywords:
randomized double;
cytosolic phospholipase;
placebo controlled;
first man;
blind placebo;
double blind
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!